A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Treatment and 14-week Extension, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Cataract Surgery
A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Treatment and 14-week Extension, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Cataract Surgery
The purpose of this study is to assess the safety and efficacy of K-321 in subjects after cataract surgery
Inclusion Criteria:
Exclusion Criteria:
Is a female subject of childbearing potential and any of the following is true:
Had intraocular surgery (non-laser surgery) in the study eye within 6 months of Visit 1.
Had intraocular laser surgery in the study eye within 3 months of Visit 1.
Meet any other exclusion criteria outlined in clinical study protocol